Elanco Animal Health Inc (NYSE: ELAN)

Elanco Animal Health Incorporated is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. The company partners with farmers pet owners veterinarians and society to create value and help customers improve animal health while making a meaningful impact on the communities served. Its purpose driven approach is encapsulated by the Go Beyond philosophy which aims to advance animal health customer success employee wellbeing and societal benefit.

The company generates revenue through the sale of a diverse portfolio of animal health products that includes parasiticides dermatology vaccines pain therapeutics and feed additives for both companion animals and livestock. Its product lineup is marketed under approximately two hundred brands and is distributed in more than ninety countries worldwide. Revenue is derived from sales to third party distributors retailers veterinarians and directly to farm animal producers and pet owners.

The company operates through a single segment focused on animal health.

• Animal Health segment encompasses the development manufacturing and commercialization of products for pets and farm animals including parasiticides vaccines pain relief treatments and feed additives that improve efficiency and support disease prevention.

Elanco Animal Health Incorporated holds a strong position in the global animal health industry competing with major players such as Zoetis Boehringer Ingelheim Animal Health and Merck Animal Health. The company leverages a broad product portfolio high impact innovation and a global sales force to maintain competitive advantage. Its recent acquisitions and internal pipeline further strengthen its market standing.

The company sells its products primarily through third party distributors retailers and directly to veterinarians and farm producers. Its largest customer is an affiliate of Cencora Inc which accounted for about twelve percent of total revenue in 2025. The second largest customer is another third party distributor representing roughly seven percent of revenue in the same year. No other customer exceeded five percent of revenue during 2025.